Medisse, A Dutch biomaterial company, successfully treated the first patient with the FlexiSurge Adhesion Barrier
EDE, The Netherlands--(BUSINESS WIRE)--Medisse BV, a leading innovator and developer of synthetic resorbable soft tissue implants, today announced the successful treatment of the first patient in a clinical trial for its first innovation, FlexiSurge® Adhesion Barrier, which is designed to reduce adhesions formed after open colorectal surgery procedures. The study, currently underway in the Netherlands, marks a significant milestone in the development of the Company’s first product to revolutionize patient care.
“We look forward to diminish the problem of adhesion formation in the future by this promising anti-adhesive film.”
The study, being conducted in three hospitals in the Netherlands, will investigate the safety of FlexiSurge, and its ability to reduce formation of adhesions after open colorectal surgery. Adhesions are formed on average in 70-90% of open abdominal surgical procedures. These adhesions can have severe clinical consequences like small bowel obstruction – with a high mortality rate-, secondary infertility in female, complications in re-operations and chronic abdominal pain. FlexiSurge has the potential to make an enormous impact on colorectal procedures and has been estimated as a $2-3B market WW.
“We are happy to have successfully treated the first patient in the FlexiSurge study,” said Prof Dr. ND Bouvy of the Academic Medical Center, Maastricht, in The Netherlands. “We look forward to diminish the problem of adhesion formation in the future by this promising anti-adhesive film.”
“The treatment of this first patient is a major milestone for our company and will be our first class 3 product in humans,” said Tjeerd Homsma, Chief Executive Officer of Medisse. “Our FlexiSurge product has the potential to revolutionize anti-adhesion treatment in abdominal surgeries and address a huge cost to society for treatment of the clinical consequences, >3B$ annually in the US alone. We are privileged to work with such a renowned group of doctors who recognize the need for this product on a daily basis.”
Medisse BV is a leading innovator and developer of synthetic resorbable soft tissue implants. The Company’s first product, FlexiSurge Adhesion Barrier, is currently tested in a clinical study to obtain the clinical data needed for CE marking early in 2015. Medisse is also developing anti-adhesive technologies for use on other implantable medical devices like eg. hernia meshes. Medisse products are currently indicated for investigational use only and have not yet been approved for medical use in any market.